Ergomed Co-Invests in Dilaforette For Sickle-Cell Disease Treatment
Author: Rowena Harris-Doughty for Morningstar News
Ergomed PLC said it has signed a co-development agreement for sickle-cell disease treatment with Swedish drug development company Modus Therapeutics AB, a company in which it will co-invest. Modus Therapeutics, a company owned by Karolinska Development AB, is developing sevuparin, a drug designed to restore blood flow and prevent further microvascular obstruction in both sickle cell disease and malaria patients.
In Thursday’s statement, Ergomed said the phase II study in sickle-cell disease patients suffering from acute Vaso-Occlusive Crisis, is planned to start in the second quarter of this year.
“Ergomed will furthermore co-invest a proportion of its revenues from the clinical and regulatory activities of the trial in return for an equity stake in Modus Therapeutics,” Ergomed said.